Cello Group plc (LON:CLL) insider Mark Bentley bought 110,000 shares of the business’s stock in a transaction on Wednesday, September 27th. The shares were acquired at an average price of GBX 128 ($1.72) per share, with a total value of £140,800 ($189,349.11).

Mark Bentley also recently made the following trade(s):

  • On Friday, September 22nd, Mark Bentley sold 150,450 shares of Cello Group plc stock. The stock was sold at an average price of GBX 126 ($1.69), for a total transaction of £189,567 ($254,931.41).

Shares of Cello Group plc (CLL) opened at 127.50 on Thursday. The stock’s 50 day moving average is GBX 124.95 and its 200-day moving average is GBX 126.43. The stock’s market capitalization is GBX 132.18 million. Cello Group plc has a one year low of GBX 94.60 and a one year high of GBX 140.00.

The company also recently disclosed a dividend, which will be paid on Friday, November 3rd. Shareholders of record on Thursday, October 5th will be paid a dividend of GBX 1.05 ($0.01) per share. This represents a yield of 0.81%. The ex-dividend date of this dividend is Thursday, October 5th.

TRADEMARK VIOLATION WARNING: This news story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/28/cello-group-plc-cll-insider-mark-bentley-acquires-110000-shares.html.

A number of equities research analysts have recently commented on CLL shares. FinnCap reiterated a “buy” rating and set a GBX 132 ($1.78) price target on shares of Cello Group plc in a report on Tuesday. N+1 Singer reiterated a “buy” rating and set a GBX 131 ($1.76) price target on shares of Cello Group plc in a report on Wednesday, September 20th.

Cello Group plc Company Profile

Cello Group plc is a United Kingdom-based healthcare and consumer strategic marketing company. The Company is engaged in providing market research, consulting and direct marketing services. The Company operates through two segments: Cello Health and Cello Signal. The Cello Health Division provides market research, consulting and communications services principally to the Company’s pharmaceutical and healthcare clients.

Receive News & Stock Ratings for Cello Group plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cello Group plc and related stocks with our FREE daily email newsletter.